目的分析ERβ2、ERα46在甲状腺乳头状癌(PTC)的表达状态、临床价值及意义。方法选择手术完整切除的甲状腺乳头状癌40份、正常甲状腺组织40份、结节性甲状腺肿40份。采用免疫组织化学技术(Immunohistochemistry,I H C)检测组织中E Rβ2...目的分析ERβ2、ERα46在甲状腺乳头状癌(PTC)的表达状态、临床价值及意义。方法选择手术完整切除的甲状腺乳头状癌40份、正常甲状腺组织40份、结节性甲状腺肿40份。采用免疫组织化学技术(Immunohistochemistry,I H C)检测组织中E Rβ2、 E Rα46表达情况,收集P T C患者术前淋巴结转移情况、临床分期及5年生存率。结果 E Rβ2、ERα46在甲状腺乳头状癌阳性表达率分别为92.5%、70.0%,2种受体在甲状腺乳头状癌和良性病变中的阳性表达差异均有统计学意义(P <0.05)。ERβ2、ERα46诊断乳头状癌的灵敏度分别为92.5%、70.0%,特异度分别为72.5%、78.8%;E Rβ2、 E Rα46的表达与甲状腺乳头状癌的临床分期及淋巴结转移有关,差异均有统计学意义(P <0. 05), 5年生存率、死亡患者ERβ2、ERα46阳性细胞率的差异无统计学意义(P>0.05)。结论 ERβ2、ERα46在甲状腺乳头状癌中表达增强,在病理诊断中有一定的价值,但对于判断远期预后的情况不明显。展开更多
Estrogen receptor beta(ERβ) is one of the two key receptors(ERα, ERβ) that facilitate biological actions of 17β-estradiol(E2). ERβ is widely expressed in many tissues, and its expression is reduced or lost during...Estrogen receptor beta(ERβ) is one of the two key receptors(ERα, ERβ) that facilitate biological actions of 17β-estradiol(E2). ERβ is widely expressed in many tissues, and its expression is reduced or lost during progression of many tumors. ERβ facilitates estrogen signaling by both genomic(classical and non-classical) and extra-nuclear signaling. Emerging evidence suggests that ERβ functions as a tissue-specific tumor suppressor with anti-proliferative actions. Recent studies have identified a number of naturally available selective ERβ agonists. Targeting ERβ using its naturally available ligands is an attractive approach for treating and preventing cancers. This review presents the beneficial actions of ERβ signaling and clinical utility of several natural ERβ ligands as potential cancer therapy.展开更多
文摘目的分析ERβ2、ERα46在甲状腺乳头状癌(PTC)的表达状态、临床价值及意义。方法选择手术完整切除的甲状腺乳头状癌40份、正常甲状腺组织40份、结节性甲状腺肿40份。采用免疫组织化学技术(Immunohistochemistry,I H C)检测组织中E Rβ2、 E Rα46表达情况,收集P T C患者术前淋巴结转移情况、临床分期及5年生存率。结果 E Rβ2、ERα46在甲状腺乳头状癌阳性表达率分别为92.5%、70.0%,2种受体在甲状腺乳头状癌和良性病变中的阳性表达差异均有统计学意义(P <0.05)。ERβ2、ERα46诊断乳头状癌的灵敏度分别为92.5%、70.0%,特异度分别为72.5%、78.8%;E Rβ2、 E Rα46的表达与甲状腺乳头状癌的临床分期及淋巴结转移有关,差异均有统计学意义(P <0. 05), 5年生存率、死亡患者ERβ2、ERα46阳性细胞率的差异无统计学意义(P>0.05)。结论 ERβ2、ERα46在甲状腺乳头状癌中表达增强,在病理诊断中有一定的价值,但对于判断远期预后的情况不明显。
基金supported by the National Natural Science Foundation of China(81073074,30472200)the fund for talents from the abroad in Hebei Province,P.R.China(200828)
基金supported by the NIH/NCI grant CA178499-01(RKV)CPRIT Training grant RP140105(GRS)2014-15 ABTA Discovery grant(GRS)
文摘Estrogen receptor beta(ERβ) is one of the two key receptors(ERα, ERβ) that facilitate biological actions of 17β-estradiol(E2). ERβ is widely expressed in many tissues, and its expression is reduced or lost during progression of many tumors. ERβ facilitates estrogen signaling by both genomic(classical and non-classical) and extra-nuclear signaling. Emerging evidence suggests that ERβ functions as a tissue-specific tumor suppressor with anti-proliferative actions. Recent studies have identified a number of naturally available selective ERβ agonists. Targeting ERβ using its naturally available ligands is an attractive approach for treating and preventing cancers. This review presents the beneficial actions of ERβ signaling and clinical utility of several natural ERβ ligands as potential cancer therapy.